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Introduction
Cholera holotoxin (CTx) is an AB5-type toxin, with its five 
B subunits assembled in a ring-shaped structure and the C ter-
minus of the A subunit protruding through the central pore 
(Fig. 1; Zhang et al., 1995). Each of the B subunits can bind 
to the surface monosialoganglioside GM1 and so allow inter-
nalization of CTx into host cells (Heyningen, 1974; Fujinaga 
et al., 2003). The A subunit projects above the plane of the 
B pentamer and exposes a protease-sensitive loop, stabilized 
by a single intramolecular disulfide bond (Zhang et al., 1995). 
Cleavage of this loop by bacterial and cell host proteases yields 
two distinct chains (CTA1 and CTA2) that remain connected via 
the disulfide bond, reduction of which is required for toxicity 
(Mekalanos et al., 1979). The CTA1 chain ADP-ribosylates the 
 subunit of the heterotrimeric GTP-binding protein Gs, trigger-
ing a series of events that lead to the opening of the chloride 
channels at the plasma membrane, with concomitant secretion 
of chloride and water (Schafer et al., 1970; Kassis et al., 1982; 
Kahn and Gilman, 1984). In the intoxicated cell, only CTA1 
reaches the cytoplasm to interact with its substrates (Fujinaga 
et al., 2003), but how CTA1 separates from the holotoxin is 
unclear, as is the identity of the channel via which CTA1 trans-
locates across membranes. The prevailing view is that upon 
binding of the B-pentamer to GM1 at the cell surface, CTx is 
endocytosed and reaches the ER (for review see Lencer and 
Tsai, 2003; Wernick et al., 2010b). The intramolecular disulfide 
bond is then reduced, a reaction that can be catalyzed by PDI, 
at least in in vitro reactions (Majoul et al., 1997; Orlandi, 1997; 
Tsai et al., 2001). CTA1 dissociates from the remainder of the 
complex to allow translocation into the cytoplasm. CTA1 may 
co-opt mechanisms used in the ER to translocate misfolded pro-
teins from the lumen of the organelle to the cytoplasm (Hazes 
and Read, 1997), a process referred to as dislocation. However, 
direct biochemical evidence for trafficking of CTA1 through the 
ER is lacking, and the identity of the portals via which CTA1 is 
translocated remain elusive.
The importance of dissecting the intoxication pathway of 
CTA1 goes beyond its impact on understanding the etiology of 
cholera disease. Because no host factor presumably evolved to 
afford pathogens a selective advantage, toxins must exploit host 
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ated N-linked glycosylation reporter peptide attached to 
CTA1, we provide direct evidence that 12% of the inter-
nalized CTA1 pool reaches the ER. We also explored 
the sortase labeling method to attach the catalytic sub-
unit of diphtheria toxin as a toxic warhead to CTA1, 
thus converting CTx into a cytolethal toxin. This new 
toxin conjugate enabled us to conduct a genetic screen 
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unappreciated differential contribution of gangliosides 
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and in zebrafish embryos (Saslowsky et al., 2010). Although 
methods to chemically label CTx with fluorophores for cell imag-
ing have been described, they do not yield homogenous popula-
tions of labeled CTx (Bastiaens et al., 1996; Bacia et al., 2002), 
making it difficult to equate distribution of fluorescence with that 
of active CTA1. The use of inhibitors of intracellular trafficking, 
such as brefeldin A (Lencer et al., 1993; Nambiar et al., 1993; 
Orlandi et al., 1993), are consistent with experiments using iso-
lated microsomes (Schmitz et al., 2000) and transfected mamma-
lian cells that overexpress CTA1 targeted to the ER by means of a 
cleavable signal sequence (Teter et al., 2002). All of these experi-
ments implicate a role for the ER in intoxication. However it is not 
clear whether these models accurately capture the physiological 
sequence of events because the cotranslational mode of ER entry 
differs from that of normal delivery routes for CTA1 and further 
assumes that the ER is the relevant exit portal. Thus, strategies to 
site-specifically and quantitatively label the toxic CTA1 chain in 
the context of a functional holotoxin would help to directly ad-
dress its intracellular trafficking.
molecular machinery to intoxicate cells. Unraveling how toxins 
traffic from one intracellular compartment to another and across 
subcellular membranes provides valuable information about 
how the mammalian cell operates. However, the difficulties in-
herent in labeling CTx or CTx structural-related toxins without 
loss of activity limit their use as research tools. Extension of the 
N terminus of CTA1 leads to its rapid degradation (Wernick 
et al., 2010a), and attempts to install, by genetic means, sizable 
protein fragments or intact proteins such as GFP in the A subunit 
loop have failed, presumably because such operations preclude 
assembly of active holotoxin. The strategies currently available 
to examine trafficking of CTA1 are limited to the use of poly-
clonal antibodies (Wernick et al., 2010a), circular dichroism/ 
fluorescence, or Fourier transform infrared spectroscopy studies 
(Pande et al., 2007; Taylor et al., 2011), and to indicators of toxic 
activity such as loss of transepithelial resistance in polarized 
cell monolayers (Lencer et al., 1992), increased levels of cAMP 
(Kassis et al., 1982), or induction of morphological altera-
tions in cells in culture (Guerrant et al., 1974; Donta et al., 1976) 
Figure 1. Schematic representation of the 
structure of CTx and of the strategy used to 
attach, in a site-specific manner, peptides 
or proteins to CTA1 in the context of the pre-
assembled holotoxin.
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bond (Cys187-199) in the A subunit meets this criterion. Because 
cleavage between Arg192 and Ser193 is a prerequisite for 
full toxicity (Mekalanos et al., 1979), we installed a sortase A 
recognition motif (LPETG) immediately preceding Pro191. 
The LPETG sequence was followed by a glycine residue, an 
HA epitope tag, and a trypsin cleavage site (Fig. 1). Upon com-
pletion of the sortase reaction, the sequence of the final product 
is quite similar to that of the cleaved native version of CTx, car-
rying two additional amino acids at the predicted C terminus 
of CTA1, with the four C-terminal residues of CTA1 differing 
from native CTA1 (Fig. 1).
The LPETG-containing A subunit sequence and the na-
tive B subunit of cholera toxin were coexpressed using a bi-
cistronic bacterial vector. Both proteins were equipped with 
signal sequences from the Escherichia coli heat-labile entero-
toxin, synthesized as precursors, and delivered to the periplasm, 
where they are processed and assembled (Jobling et al., 1997). 
We purified the holotoxin by exploiting the intrinsic ability of 
the B-subunit to bind to Ni2+ (Dertzbaugh and Cox, 1998), fol-
lowed by anion-exchange chromatography to resolve the AB5 
complex from the B pentamer (Fig. 2, A and B).
To determine whether extension of the loop was still com-
patible with formation of the intramolecular disulfide bond, we 
analyzed our modified version of CTx by SDS-PAGE under re-
ducing and nonreducing conditions (Fig. 2 C). Upon incubation 
with trypsin, the 29-kD CTA (CTA1 + CTA2) polypeptide shifts 
to 24 kD only under reducing conditions (Fig. 2 C, +trypsin, 
compare with ±DTT); this 24-kD species corresponds to CTA1 
separated from CTA2. We attribute the slight difference in mo-
bility observed for CTA under nonreducing conditions (Fig. 2 C, 
compare ±trypsin and DTT) to a change in SDS binding and 
shape, caused by the opening of the loop by trypsin. Altogether, 
this shows that the LPETG-containing version of CTx retains 
the ability to fold into the native structure. This toxin preparation 
also retains biological activity, as we found it indistinguishable 
from the unmodified CTx at eliciting morphological aberrations 
in Vero cells, even at low concentrations (Fig. 2 D).
Installation of small peptides at the  
C terminus of CTA1
Our initial attempts to label the modified CTx version showed 
that sortase A was inefficient at cleaving the LPETG-containing 
loop. Although flexible, the loop region might still impose con-
straints that hinder proper exposure of the sortase recognition 
motif. We solved this issue by using trypsin (EC 3.4.21.4) to nick 
the loop before the sortase reaction (Fig. 1). Sortase-mediated 
reaction conditions to label CTA1 were optimized using short 
oligoglycine peptides that contained either a biotin or a fluoro-
phore (Fig. 3, A and B, top panels; and Fig. S1). We moni-
tored labeling by SDS-PAGE/fluorescence imaging (for Alexa 
Fluor 647) or SDS-PAGE/immunoblotting (for biotin; Fig. 3, 
A and B, bottom). Because the HA tag is located C-terminally 
to the LPETG site, it is removed upon cleavage by sortase 
(Fig. 1, bottom). The extent of labeling can thus be assessed 
by the loss of anti-HA immunoreactivity. However, loss of the 
HA tag could also result from hydrolysis of the acyl-enzyme 
intermediate without formation of a labeled CTA1 product. 
Labeling through chemical modification, although conve-
nient and straightforward, is rarely quantitative or site-specific. 
Modification of multiple surface-exposed amino acid side chains 
might compromise trafficking behavior or biological activity of 
CTx. A further complication is the paucity of exposed lysine or 
cysteine residues that lend themselves to chemical modifica-
tion on CTA1. Also, the quaternary structure of the holotoxin 
is maintained only under mild conditions of labeling, not neces-
sarily compatible with efficient chemical modification of CTx. 
Recently developed enzymatic methods for protein modifica-
tion require either installation of sizable catalytic tags (such as 
SNAP-tags, 20 kD; Keppler et al., 2003) that cannot be geneti-
cally engineered into the CTA subunit loop without compromis-
ing holotoxin assembly, or installation of the 15–amino acid BirA 
acceptor peptide (Chen et al., 2005), the use of which is limited 
to the enzymatic installation of biotin and its synthetically chal-
lenging derivatives. To overcome these hurdles and to achieve 
efficient site-specific labeling of CTx, we have exploited the 
bacterial enzyme sortase A from Staphylococcus aureus.
Sortase A recognizes and cleaves a specific short motif, 
LPXTG (where X is any amino acid), appended to the protein 
of interest (Navarre and Schneewind, 1994). Cleavage occurs 
between the threonine and glycine residues, with the concomi-
tant formation of an acyl enzyme intermediate between the 
enzyme and its substrate. This intermediate can be resolved via 
nucleophilic attack by an added oligoglycine peptide, resulting 
in the formation of a covalent bond with the LPXTG-containing 
protein at the site of cleavage. Because the oligoglycine peptide 
tolerates decoration with any substituent of choice, the final 
product can be labeled with a fluorophore, a photoaffinity probe, 
lipids, photocrosslinkers, or even other polypeptides (Ton-That 
et al., 1999; Popp et al., 2007; Antos et al., 2008; Tsukiji and 
Nagamune, 2009; Popp and Ploegh, 2011).
We cloned the sortase A recognition motif into the A sub-
unit loop of CTx and devised a strategy to enable site-specific 
attachment of molecules to the C terminus of the catalytic CTA1 
subunit in an otherwise preassembled and correctly folded CTx. 
Here, we exploit this method not only to create a version of 
CTA1 that reports on its possible delivery to the ER, but also to 
convert CTx from a toxin that merely elevates cAMP levels into 
a cytolethal entity for use as the selecting agent in a genetic 
screen in human haploid cells (Carette et al., 2009, 2011). This 
approach identified host factors essential for intoxication by 
CTx and allowed isolation of mutant cells with defects along 
the biosynthetic pathway of gangliosides. Our results shed new 
light on the role of various ganglioside synthetic pathways in 
the construction of receptors for CTx.
Results
Strategy to specifically label the  
C terminus of CTA1 in the context  
of the holotoxin
A sortase-catalyzed reaction requires exposure of the recogni-
tion sequence in a flexible/unstructured region (Popp et al., 
2007). Based on the available crystal structure of CTx (Zhang 
et al., 1995), the loop formed by the intramolecular disulfide 
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Figure 2. Purification and characterization of CTx containing a sortase A recognition motif in the loop. (A) CTx was expressed in E. coli. Lysed cells were 
centrifuged and the supernatant (lane T, equivalent of 200 µl of culture) was incubated with Ni-NTA agarose beads. The flow-through was discarded (lane 
FT, equivalent of 200 µl culture); the bound protein was eluted with imidazole (lane E, equivalent of 2 ml of culture) and further purified by ion-exchange 
chromatography (lane MQ, equivalent of 2 ml of culture). Lane MW shows molecular weight markers in kilodaltons. (B) Affinity chromatography profile for 
purification of the sortaggable CTx version: holocomplex (fractions 47–49), B pentamer only (fractions 40–44), and contaminants (fraction 65). (C) Puri-
fied CTx was incubated with trypsin or left untreated and analyzed under reducing and nonreducing conditions. All panels show SDS-PAGE gels stained 
with Coomassie. (D) Cellular toxicity assay for nonmodified CTx (Native CTx), wild-type, and inactive mutant (E110D/E112D) in the sortaggable version 
(CTx.LPETG and mutCTx.LPETG), and CTx labeled with Alexa Fluor 647 (CTx-Alexa 647) or biotin (CTx-biotin) at the C terminus of CTA1. Vero cells were 
intoxicated with 2 nM of the different versions of CTx for 2 h at 37°C. Phase-contrast images are shown. Insets on the top right corner show magnified 
views of the boxed regions. Bar, 100 µM.
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the dislocation of CTA1 (Schmitz et al., 2000; Tsai et al., 2001; 
Winkeler et al., 2003; Bernardi et al., 2008; Bernardi et al., 
2010). Independent experimental approaches have failed to 
confirm some of these proposals (Saslowsky et al., 2010). Also, 
the ER retention signal at the C terminus of CTA is apparently 
not essential for intoxication, as disruption of the KDEL motif 
does not abolish toxicity (Lencer et al., 1995), unlike what is 
seen for Pseudomonas aeruginosa exotoxin A (Chaudhary 
et al., 1990).
To determine whether CTA1 indeed traffics through the 
ER in vivo, we used sortase to attach a bifunctional probe con-
taining a biotin for specific detection of CTA1, and two con-
sensus sites for N-linked glycosylation (only one of which 
would likely be used) to the C terminus of CTA1 (Fig. 4 A, 
G3K(biotin)NNSTG). If CTA1 reaches the ER, then glycosyl-
ation should occur, provided the N-linked glycan attachment 
site is accessible to the glycosylation machinery. Genetic mod-
ification of toxins such as ricin with an N-glycosylation site to 
report on trafficking through the ER has been exploited before 
(Rapak et al., 1997).
To infer the maximum contribution of hydrolysis, we included 
a control reaction from which the oligoglycine peptide was 
omitted altogether. We show that near-quantitative (95%) 
labeling of CTA1 is achieved with both biotin and fluoro-
phores (Fig. 3, A and B, bottom). As expected, sortase A 
does not react with the B subunit of CTx (CTB) in these re-
actions, as the B subunit lacks a sortase A recognition motif. 
Both CTx-biotin and CTx-fluorophore are toxic even at low 
concentrations (Fig. 2 D).
At least 12% of the CTA1 pool that 
enters the cells traffics through the ER
Although it has been widely assumed that delivery and trans-
location of CTA1 across the ER is required for intoxication 
(Wernick et al., 2010b), the evidence on which the conclusion of 
ER involvement rests is for the most part indirect: it is based on 
pharmacological inhibition of trafficking by brefeldin A (Lencer 
et al., 1993; Nambiar et al., 1993; Orlandi et al., 1993), on the 
trafficking behavior of the B subunit (Fujinaga et al., 2003), or 
on in vitro experiments implicating ER-resident proteins in 
Figure 3. Labeling of the C terminus of CTA1 with small peptides in the context of the preassembled holotoxin. Purified sortaggable CTx was treated with 
trypsin and then incubated with sortase A in the presence of either a biotin-containing peptide (A) or an Alexa Fluor 647–containing peptide (B) as indi-
cated. The structures of the corresponding peptides are shown in the top panels. Probes are appended to CTA1 quantitatively as assessed by Coomassie 
staining, fluorescence imaging, and streptavidin blotting, and by the loss of anti-HA immunoreactivity upon reaction (see text for details), as shown in the 
bottom panels. Lane MW shows molecular weight markers in kilodaltons.
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Installation of a correctly folded protein at 
the C terminus of CTA1
The catalytic subunit of diphtheria toxin (DTA) recognizes diph-
thamide, a modified histidine residue in eukaryotic elongation 
factor 2 (eEF-2), ADP-ribosylates it to block protein synthesis, 
and so causes cell death (Collier, 2001; Liu et al., 2004). To kill 
cells, DTA needs to access the cytoplasm where diphthamide-
modified eEF-2 is located. However, without its receptor-binding 
subunit, DTA fails to even enter the cell. Thus, if a fusion of CTx 
with DTA could mediate binding to cells and delivery of the 
DTA payload to the cytoplasm, toxicity should be observed. We 
could then use the CTx–DTA conjugate to perform a lethality-
based genetic screen in human haploid cells to identify host 
factors essential for intoxication, as has been done for the native 
diphtheria toxin (DTx; Carette et al., 2009).
DTA (189 amino acids) is much larger than the short pep-
tides tolerated as genetic fusions with CTx (21 amino acids; 
Wernick et al., 2010a), and therefore sortase-mediated reactions 
are an attractive alternative approach. We reasoned that a chemo-
enzymatic transformation of an already assembled holotoxin 
would overcome the issues associated with genetic extensions 
of CTA1, which have proven problematic exactly because they 
interfere with holotoxin assembly. To use DTA as a nucleophile 
We monitored the fate of CTx-G3K(biotin)NNSTG over 
time by immunoblotting analysis of total cell lysates using 
streptavidin-HRP. At 45 min after intoxication, we detected 
an electrophoretically distinct form of CTA1, the levels of 
which increased with time (Fig. 4 B, top). The apparent mole-
cular mass difference of the two streptavidin-reactive CTA1 spe-
cies is consistent with the acquisition of an 3-kD N-glycan, 
which suggests the use of a single N-glycosylation site. We 
confirmed the presence of an N-linked glycan by digestion 
with EndoH and PNGaseF (Fig. 4 C). At no time did we de-
tect EndoH-resistant material, which showed that the high-
mannose glycans attached to CTA1 were not converted into 
hybrid/complex-type N-linked oligosaccharides. We there-
fore conclude that CTA1, once glycosylated, does not enter 
the more distal portions of the secretory pathway, at least 
within the time frame of our experiment. Based on densito-
metric analysis, we estimate that a minimum of 12% of 
cell-bound CTA1-G3K(biotin)NNSTG reaches the ER, as 
 assessed by N-glycosylation (Fig. 4 B, bottom). Combined, 
these results show that sortase-mediated modifications at the 
C terminus of CTA1 are possible with retention of CTx qua-
ternary structure, cell binding, and toxicity, and that the mod-
ified CTA1 reaches the ER.
Figure 4. A fraction of CTA1 that enters the cell traffics through the ER. (A) Structure of the glycosylation reporter probe used. (B, top) Vero cells were 
intoxicated with CTx-G3K(biotin)NNSTG. Glycosylation of modified CTx was followed in time by Streptavidin-HRP blotting on total cell lysates. GAPDH 
detected by immunoblotting was used as a loading control. Background biotinylated protein bands in the lysate are marker with an asterisk. (B, bottom) 
Quantification of the amount of CTx-G3K(biotin)NNSTG that is glycosylated over time. The mean of three independent experiments ± SD is shown (error 
bars). The percentage of the total is defined as the ratio of either glycosylated or nonglycosylated forms of CTA1/levels of CTA1 at time point 0. (C) Vero 
cells intoxicated with CTx-G3K(biotin)NNSTG were harvested at different time points and treated with Endo H (H) and PNGase F (F). CTA1-CHO is the 
N-glycosylated version of CTA1.
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DTx panels), which indicates that any morphological altera-
tions detected with CTx–DTA derive solely from the activity 
of CTx.
Human haploid genetic screens using the 
CTx–DTA conjugate
Based on our results, we hypothesize that DTA coupled to CTx 
traffics along the GM1 pathway (the receptor for CTx), an atypical 
route for DTA because the receptor for DTx is the heparin-
binding EGF-like growth factor (Naglich et al., 1992). We further 
conclude that DTA is unable to exit from a compartment along 
the CTx intoxication route to the cytoplasm, unless assisted by 
CTA1 as its covalent fusion partner (Fig. 5 C). Dislocation of 
CTA1 would then be the rate-limiting step in delivering the DTA 
payload to the cytoplasm. A genetic screen performed with the 
CTx–DTA conjugate would thus identify genes involved in 
binding/trafficking of CTx from the plasma membrane to the 
cytoplasm, as well as genes involved in the biosynthetic pathway 
of diphthamide (the substrate for DTA). Genes encoding the 
cytosolic target substrates of CTA1 would not be found, as cells 
harboring mutations in those genes can still be killed by DTA.
We performed a genetic screen as described previously 
(Carette et al., 2011) using a pool of 100 million mutagenized 
haploid cells. Upon intoxication with the CTx–DTA conjugate, 
we expanded surviving cells, amplified the insertion sites, and 
subjected them to deep sequencing (Carette et al., 2011). We 
mapped the insertion sites to the human genome and identified 
those genes significantly enriched for disruptive mutations as 
compared with a control population of unselected mutagenized 
cells. This yielded seven candidate host factors with highly sig-
nificant scores (P-values between 4 × 104 and 5 × 10120; Fig. 6 A 
and Tables S1 and S2). We identified DPH2 and WDR85, genes 
involved in diphthamide biosynthesis and previously found in a 
haploid screen with DTx (Liu et al., 2004; Carette et al., 2009); 
ELF4, a member of the ETS family of transcription factors 
(Miyazaki et al., 1996), with its role in trafficking of CTx un-
known; and ST3GAL5, SLC35A2, B3GALT4, and UGCG, genes 
whose products are involved in ganglioside biosynthesis (for 
review see Maccioni et al., 2011; Fig. 6 B), therefore affecting 
the levels of GM1 essential for binding of CTx to the cell. Using 
a fluorescently labeled version of CTx prepared via sortase- 
mediated reaction (CTx-Alexa647, Fig. 3 B), we show that CTx 
binds to WDR85-deficient cells but not to the SLC35A2 mutant 
(Fig. 6 C, WDR85GT vs. SLC35A2GT). However, toxin binding 
to the latter was readily restored by complementation with the 
respective cDNA (Fig. 6 C, SLC35A2 restored). We also ob-
served binding of CTx-Alexa647 to a subset of ST3GAL5 mutant 
cells. The same result was obtained in two independent clonal cell 
lines with gene trap insertions in the ST3GAL5 locus (Fig. 6 C, 
ST3GAL5GT#1 and ST3GAL5GT#2). The existence of a mixed 
cell population (i.e., high- and low-binding CTx) was confirmed 
by flow cytometry. The majority of the ST3GAL5-deficient cells 
do not stain with CTx-Alexa647 (Fig. 6 D, ST3GAL5 low), but 
a minor fraction of cells (5–10%) bind CTx-Alexa647 at lev-
els comparable to wild-type KBM7 cells (Fig. 6 D, ST3GAL5 
high). To determine whether CTx binding to ST3GAL5 cells 
could be the result of cross-contamination of cells or of partial 
in these reactions, we expressed it recombinantly with an 
N-terminal hexahistidine handle for purification, followed by a 
thrombin cleavage site, and five glycines (His6 LVPR^G5DTA), 
a preparation readily purified by Ni-NTA and size exclusion 
chromatography. The His6 LVPR^G5DTA protein was cleaved 
with thrombin to remove the hexahistidine tag and so expose 
the required glycines at the N terminus (Antos et al., 2009). 
G5DTA readily labels the C terminus of CTA1 in a sortase- 
catalyzed protein ligation reaction and does so with remarkable 
efficiency (>90%), based on the levels of conversion of CTA1 
to CTA1-G5DTA. Only in the reaction that contains all neces-
sary components—sortase A, the sortaggable version of CTx, 
and the protein-based nucleophile—do we observe a polypep-
tide of the mass expected for a successful ligation (Fig. 5 A, 
CTA1.G5DTA). “Sortaggable” CTx represents the sequence of 
CTx containing the sortase recognition motif LPETG installed 
in the CTA loop (Popp et al., 2007). The identity of the ligation 
product was confirmed by sequence analysis, including iden-
tification of the junction peptide between CTA1 and G5DTA 
(Fig. 5 A and Fig. S2).
Using serial dilutions of the sortase reaction mixtures, 
we intoxicated KBM7 and Vero cells and measured their via-
bility using a XTT colorimetric assay. We observed no cyto-
toxicity when CTx, sortase A, and G5DTA were admixed but not 
covalently linked (Fig. 5 B, WtCTx + DTA and SortA + DTA). 
In contrast, cell death is detected only upon intoxication with 
the enzymatically prepared CTx–G5DTA conjugate (Fig. 5 B, 
WtCTx  DTA). A similar effect (albeit showing slightly less 
toxicity) is observed using a nontoxic derivative of CTA1 
(E110D/E112D) at the catalytic site (Fig. 5 B, MutCTx-DTA; 
Jobling and Holmes, 2000, 2001), which indicates that the ob-
served toxicity indeed derives solely from the activity of DTA. 
Thus, the CTx–DTA conjugate is functional and indicates that 
CTx mediates transport of DTA from the plasma membrane to 
the cytoplasm.
Because CTx traffics through the endosomal/lysomal 
(E/L) system (Wernick et al., 2010b), toxicity of the CTx–DTA 
conjugate might result from the ability of DTA to cross E/L 
membranes into the cytoplasm (Collier, 2001) without having 
to be transported by CTA1, and with the role of CTx reduced to 
simply substituting for the receptor binding subunit of diphthe-
ria toxin (DTx). Although we cannot formally exclude this pos-
sibility, the fact that we do not detect morphological alterations 
in Vero cells with the WtCTx–DTA conjugate in the presence 
of brefeldin A (+BFA, Fig. 5 C) suggests otherwise. BFA inhib-
its vesicular trafficking, causing redistribution of the Golgi ap-
paratus and the trans-Golgi network (Fig. 5 C, Giantin panels, 
compare ±BFA; Doms et al., 1989; Lippincott-Schwartz et al., 
1989), but it does not impair trafficking of DTA from the E/L 
system to the cytoplasm (Yoshida et al., 1991). Thus, if trans-
port of the CTx–DTA conjugate to the cytoplasm was sustained 
by the DTA moiety, we should have detected morphological 
alterations in Vero cells even in the presence of BFA. This is 
not the case: we observe intoxication only in the absence of 
BFA (Fig. 5 C, compare CTx and CTx–DTA panels, ±BFA). 
In the short time frame of this experiment, no cellular morpho-
logical alterations or death were observed with DTx (Fig. 5 C, 
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Different toxin-binding patterns thus do not arise from genetic 
variation but most probably result from different states of the 
clonal cells, for example because of cell cycle–dependent changes 
in receptor expression. When the FACS-sorted ST3GAL5  
reversion, we FACS sorted the two subpopulations (ST3GAL5 
high and ST3GAL5 low) and performed RT-PCR analysis. 
ST3GAL5 transcripts were absent from both samples (Fig. 6 E), 
showing that both clonal derivatives are true nulls for this gene. 
Figure 5. Preparation and characterization of the Ctx–DTA conjugate. (A) Attachment of the catalytic subunit of diphtheria toxin (G5DTA) to the CTA1 
chain of preassembled CTx holotoxin. The sortaggable version of CTx was incubated with sortase A in the presence and absence of G5DTA (see text for de-
tails). G5DTA is appended to CTA1 quantitatively as assessed by Coomassie staining. The identity of the polypeptide corresponding to CTA1-G5DTA fusion 
was determined by electrospray ionization tandem mass spectrometry. The peptides identified are highlighted in red. The asterisk indicates a contaminant 
protein band in our DTA preparation. (B) Cytotoxicity of each of the sortase-mediated reactions shown in A was tested in KBM7 (left) and in Vero (right) 
cells. DTx corresponds to the native diphtheria holotoxin and is used as a positive control. Each data point represents the mean (n = 3) ± SD (error bars). 
“+” indicates separate addition of two unlinked molecules and “” indicates covalent linkage of DTA to CTx. (C) Cytotoxicity of the CTx–DTA conjugate 
in Vero cells in the absence or presence of 100 ng/ml brefeldin A. Cells were intoxicated with 2 nM of each toxin for 2 h at 37°C, fixed, permeabilized, 
and stained with phalloidin, anti-giantin, and Hoechst. Note that the phalloidin staining changes only in the absence of BFA and when cells are intoxicated 
with either CTx or CTx–DTA. Bar, 10 µm.
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not kill KBM7 cells, which precludes the use of such screens to 
identify host factors for CTx trafficking. We overcame this 
problem by attaching a toxic warhead to CTA1 in the context of 
the CTx holotoxin, thus converting it into a lethal entity. Be-
cause a genetic screen had been conducted with native DTx 
(Carette et al., 2009), we chose to conjugate its toxic subunit 
DTA to CTx, so a comparison of hits obtained in both screens 
(i.e., DTx and CTx–DTA) would allow an unambiguous assign-
ment of genes that specifically contribute to binding and/or traf-
ficking of CTx.
Successful installation of protein-sized moieties such as 
GFP by genetic fusion with CTA1 in the context of the holo-
toxin has never been reported, and genetic fusion of a short se-
quence to the N terminus of CTA1 lead to rapid degradation 
subpopulations were cultured to obtain yet new clonal deriva-
tives, again a mixture of high- and low-binding CTx subpop-
ulations was obtained (unpublished data). Differential binding 
of CTx-Alexa647 to the ST3GAL5 mutant cells may reflect cell 
cycle–dependent variation in the levels of GM1b ganglioside 
from the 0 series, the synthesis of which is independent of the 
activity of GM3 synthase (Fig. 6 B; Yamashita et al., 2003; 
Simpson et al., 2004), as discussed below.
Discussion
Haploid genetic screens using human KBM7 cells have allowed 
identification of host factors essential for intoxication by differ-
ent cytolethal bacterial toxins (Carette et al., 2011). CTx does 
Figure 6. Human haploid genetic screen using the CTx–DTA conjugate. (A) Candidate host factors essential for intoxication by CTx–DTA as identified in 
the haploid genetic screen. Genes significantly enriched for gene-trap insertions in the CTx–DTA–selected cell population as compared with the nonselected 
mutagenized cell population. Circles represent genes and their sizes correspond with the number of independent insertions identified in the CTx–DTA 
selected cell population. Significantly enriched genes are labeled with gene names. Genes are ranked on the x axis based on their chromosomal location. 
N indicates the number of gene trap insertions found in each gene. (B) Representation of the ganglioside biosynthetic metabolic pathway indicating the 
essential genes identified in the CTx–DTA genetic screen. The figure was prepared based on data from Yamashita et al. (2003) and Maccioni et al. (2011). 
(C) CTx-Alexa647 and Lysotracker were added to mutant clonal cells identified in the genetic screen (WDR85GT, SLC35A2GT, and ST3GAL5GT). SLC35A2 
mutant cells reconstituted with the respective defective cDNA (SLC35A2 restored) regain the ability to bind CTx. Bars, 10 µm. (D) Flow cytometry analysis 
of Alexa Fluor 647–positive cells upon intoxication of the different cell lines with various concentrations of CTx-Alexa647: 0, 0.2, 1, 2, and 10 nM (gray, 
orange, green, blue, and red, respectively) for 15 min on ice. The data shown are representative of independent experiments. (E) The low (L) and high (H) 
CTx-Alexa647 binding populations of ST3GAL5 were FACS sorted, and total RNA was isolated. RT-PCR analysis showed undetectable ST3GAL5 mRNA 
levels in two independent clonal cells containing gene trap insertions in the ST3GAL5 locus.
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cytoplasmic proteins that could obviously participate in the 
transport of CTA1 from a subcellular compartment to the cyto-
plasm were identified. We offer four explanations to account 
for this observation: first, our screen may not have reached 
saturation, a possibility supported by the absence of mutants 
in other genes (DPH1 and DPH5) known to be involved in 
diphthamide synthesis, even though we have shown that such 
genes can be successfully targeted in this approach (Carette 
et al., 2009). Second, genes involved in the dislocation of CTA1 
may be essential for cell survival, and therefore cells carrying 
disruptive gene-trap insertions in such genes may be purged 
from the mutagenized pool of cells used to conduct the genetic 
screen. Third, the CTx–DTA conjugate might reach the cytosol 
using a trafficking route that is not usually exploited by CTA1. 
Although in the presence of BFA the typical morphological 
alterations of intoxication by CTx are not detected (Fig. 5 C), it is 
still possible that a minor fraction of CTA1–DTA, sufficient to 
kill the cell, reaches the cytosol and thus eliminates cells mutant 
in genes normally important for intoxication by CTx. Fourth, 
CTA1 might reach the cytoplasm using more than one pathway. 
Whether endosomal and/or Golgi compartments are competent 
to allow egress of CTx is open to debate. Escape from compart-
ments other than the ER could explain why a mutation in the 
C-terminal KDEL retrieval signal of CTA does not eliminate 
toxicity of CTx (Lencer et al., 1995), whereas for the ADP- 
ribosylating P. aeruginosa exotoxin A, the homologous ER 
retrieval signal is essential for intoxication (Chaudhary et al., 
1990). Also, redundant pathways may support intoxication by 
CTx: if a main route is blocked by mutation of a key component, 
an alternative route may still be used. Deficiency in proteins 
involved in dislocation of misfolded proteins is compensated by 
adjustments in the expression of other components: members of 
the Derlin-nucleated dislocation complex—Sel1L, Hrd1, OS9, 
and Ubc6e—are all up-regulated in response to the complete 
absence of Derlin-2 (Dougan et al., 2011). Although involve-
ment of Derlin-1 in dislocation of CTA1 has been claimed 
(Bernardi et al., 2008; Dixit et al., 2008), it was not confirmed 
in a recent screen performed in zebrafish embryos (Saslowsky 
et al., 2010). Instead, the latter approach pointed to flotillin-1 
and flotillin-2 as protein players in trafficking of CTx. Nei-
ther of these proteins was identified in our genetic screen, most 
probably because flotillin mutant cells do not confer complete 
resistance to CTx (Saslowsky et al., 2010). The same holds true 
for torsinA, an ER membrane protein recently implicated in 
dislocation of CTA1 (Nery et al., 2011). Any fotillin- or torsinA-
deficient cells would have been purged from the mutant 
pool over the intoxication period of time required to select a 
 manageable population of surviving resistant cells.
Our genome-wide strategy positively identified genes 
involved in the synthesis of gangliosides as essential for intoxica-
tion by CTx. The assigned receptor for CTx is the ganglioside 
GM1, and so identification of UGCG and SLC35A2 is in line 
with expectations, as disruption in either one of these genes im-
pairs the synthesis of lactosylceramide, the precursor of the en-
tire series of gangliosides. Identification of the B3GALT4 gene 
was also expected, as it encodes GM1 synthase, which cata-
lyzes the synthesis of both GM1a and GM1b gangliosides 
of the modified subunit (Wernick et al., 2010a). Thus, to be 
able to modify the C terminus of CTA1 in the context of a pre-
assembled holotoxin, we developed sortase-mediated reactions. 
Sortase recognizes a five–amino acid motif, which we placed 
in the loop that connects CTA1 and CTA2, with preservation 
of the intrachain disulfide bond present in the CTA precursor. 
Optimal conversion of CTA1 into labeled CTA1 requires prior 
nicking of this loop with trypsin to fully expose the sortase 
recognition motif. We first validated the sortase-based label-
ing method using biotin and fluorophore-containing peptides to 
demonstrate that transformations at the C terminus of CTA1 
are possible without compromising CTx quaternary structure, 
receptor binding, and entry. The sortase recognition motif, the 
installation of biotin, and the installation of Alexa Fluor 647 at 
the C terminus of CTA1: none of these compromise toxicity of 
CTx as inferred from the morphological changes elicited by the 
modified toxins.
Using sortase to attach a biotinylated N-linked glycosyl-
ation reporter peptide to the C terminus of CTA1 in the con-
text of the holotoxin, we could show arrival of CTA1 in the 
ER. Previous evidence for delivery of CTA1 to the ER came 
from experiments using a genetically engineered CTB subunit 
with a glycosylation recognition motif, but only a minor frac-
tion of CTA1 was immunoprecipitated along with glycosylated 
and therefore ER-resident CTB (Fujinaga et al., 2003). Because 
the intracellular distribution of oxidoreductases is not confined 
to the ER (Arunachalam et al., 2000), if reduction of the di-
sulfide bond that links CTA1 and CTA2 had occurred in other 
subcellular compartments, then CTA1 could have trafficked in-
dependently of CTB for intoxication to occur. Also, glycosyl-
ated CTB could have re-associated with free CTA1 upon lysis 
of intoxicated cells. Here we estimate that at least 12% of the 
fraction that enters the cells engages the host glycosylation ma-
chinery in the ER. This is a minimum estimate, as the efficiency 
of glycosylation of the modified CTA1-GGGK(biotin)NNSTG 
may fall well short of completeness.
Having established conditions to modify CTx using sor-
tase, and having shown that the modified versions retained key 
features of native CTx, we attached the far more bulky catalytic 
subunit of diphtheria toxin, DTA, to CTA1. The resultant con-
jugate was cytotoxic to both Vero and KBM7 cells and could 
therefore be used to perform a genetic screen in KBM7. It is the 
CTx portion that must dictate trafficking of CTx–DTA because 
brefeldin A has a protective effect toward CTx–DTA, but not 
toward diphtheria holotoxin activity (Yoshida et al., 1991). This 
suggests that the mechanisms used by CTA1 to reach the cyto-
plasm involve components that can accommodate passage of 
even a modestly sized protein like DTA (21 kD, about the same 
as that of CTA1 itself) when covalently attached to CTA1.
The CTx–DTA conjugate was then used to perform a 
genetic screen in KBM7 cells (Carette et al., 2009; Carette et al., 
2011). Among the identified hits were proteins involved in the 
synthesis of diphthamide (the substrate for DTA and hence 
entirely expected) and gangliosides (the entry factor for CTx). 
Although 98% of the expressed genes carry insertions in the 
pool of mutants that serves as the starting population for our 
genome-wide screen (Carette et al., 2011), no ER-resident or 
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toxins with a robust genetic screening approach, as described 
here, can extend the range of tools to address intracellular traf-
ficking more generally.
Materials and methods
Cloning and expression of the sortaggable version of CTx
The LPETG.G.HA sequence was introduced into the loop of CTA1 using a 
QuikChange II site-directed mutagenesis kit (Agilent Technologies) and the 
following oligonucleotides: 5-GGTTGTGGGAATGCTCTTCCTGAGACCG-
GTGGTTACCCATACGATGTT-3 and its reverse-complement counterpart. 
The template used was a bi-cistronic arabinose-inducible pARCT plasmid 
encoding CTA and CTB proteins with the corresponding signal peptides 
of the E. coli heat-labile enterotoxin II subunits (a gift from W. Lencer, Chil-
dren’s Hospital Boston, Harvard Medical School, Boston, MA). The inac-
tive mutant E110D/E112D was created by site-directed mutagenesis using 
the following oligonucleotides: 5-AGTCCTCATCCAGATGACCAAGAC-
GTTTCTGCTTTAGGTGG-3 and its reverse-complement counterpart. The 
template used was the plasmid encoding the sortaggable version of CTx. A 
single protocol for expression and purification of the different CTx versions 
was used. In brief, the various constructs were transformed into the E. coli 
BL21strain (Promega). A stationary phase starter culture prepared in sterile 
lysogeny broth (LB) media supplemented with 35 µg/ml chloramphenicol 
was diluted 50 times with freshly prepared nonautoclaved Terrific Broth 
media (Sigma-Aldrich) supplemented with chloramphenicol. At mid-log 
phase, expression of CTA and CTB proteins was induced with 0.25% (wt/vol) 
arabinose (Sigma-Aldrich) for 3 h at 37°C. Cells were harvested and 
resuspended in 50 mM Tris-Cl, 300 mM NaCl, and 1 µg/ml polymixin B 
(Sigma-Aldrich), pH 8.0, supplemented with protease cocktail inhibitors 
(Roche). The suspension was stirred at 25°C for 30 min and centrifuged 
at 10,000 g. The supernatant was incubated with Ni-NTA agarose (QIA-
GEN; 0.25-ml bed volume per 1 liter culture) for 30 min at 25°C. The 
resin was washed with 20 column volumes of 50 mM Tris-Cl and 300 mM 
NaCl, pH 8.0, and the protein was eluted with 20 mM Tris-Cl, 150 mM 
NaCl, and 300 mM imidazole, pH 8.0. CTx was further purified by 
anion-exchange chromatography on a Mono-Q column (GE Healthcare) 
and eluted using a linear salt gradient generated with 20 mM Tris-Cl, pH 
8.0, 20 mM Tris-Cl, and 1 M NaCl, pH 8.0. Fractions containing the holo-
toxin were analyzed by SDS-PAGE and Coomassie staining, pooled, and 
concentrated. 10% glycerol was then added. The protein preparation was 
aliquoted, snap frozen, and stored at 80°C. The protein concentration 
was determined by Bradford Assay (Bio-Rad Laboratories).
Synthesis of GGGK-Alexa647 and GGGK(biotin)NNSTG
The GGGK peptide was synthesized manually by standard Fmoc-based 
solid-phase peptide synthesis protocols on Rink Amide resin (Novabio-
chem; EMD). The Fmoc-protected peptide was cleaved from the resin 
by treatment with 2.5 mL of 95:3:2 TFA/TIPS/H2O (5×, 15 min each) 
that also removed the 4-methyltrityl (Mtt) protecting group on the lysine 
residue. The combined cleavage solutions were concentrated, dissolved 
in methanol, and precipitated with cold diethyl ether. Coupling of the 
Fmoc-protected peptide to the amine-reactive Alexa Fluor dye was accom-
plished in solution. One equivalent of Fmoc-GGGK peptide was mixed 
with 0.5 equivalents of Alexa Fluor 647 carboxylic acid, succinimidyl 
ester (Invitrogen), and four equivalents of N,N-Diisopropylethylamine 
(Sigma-Aldrich) in anhydrous DMSO, then incubated at room temperature 
for 6 h. Under these conditions, Fmoc deprotection also occurred. The 
Alexa Fluor 647 peptide was purified on a 5PE column (8 × 250 mm, 
MeCN/H2O gradient mobile phase with 0.1% TFA, 3 mL/min; Waters). 
We were unable to observe the Alexa Fluor 647 peptide with a matrix-
assisted laser desorption/ionization time-of-flight mass spectrometer, so we 
inferred the molecular weight and activity as a nucleophile by setting up 
a test transpeptidation reaction with sortase A and an LPETG-tagged GFP 
substrate as described previously (Popp et al., 2007), then observing the 
mass change in the transpeptidation product by electrospray ionization 
mass spectrometry on a liquid chromatography mass spectrometer (Micro-
mass MS Technologies), an HPLC system equipped with an HTC PAL 
autosampler (Paradigm MG4; Michrom BioResources), and a Symmetry 
5 mm C8 column (2.1 × 50 mm, MeCN/H2O (0.1% formic acid) gradient 
mobile phase, 150 ml/min; Waters). The predicted molecular weight for 
the Alexa Fluor 647 peptide is 1,155.06 g/mol, obs = 1155.0 g/mol. 
The GGGK(biotin)NNSTG peptide was synthesized using standard solid 
phase peptide synthesis.
(Maglione et al., 2010; Maccioni et al., 2011). In contrast, 
implication of the ST3GAL5 gene in CTx intoxication was 
unexpected and adds a new twist to our understanding of 
ganglioside biosynthesis in its relation to CTx intoxication. 
The ST3GAL5 gene product is involved in the synthesis of 
GM3, which is not only a precursor for GM1a but also for most 
of the more complex ganglioside lipids (Yamashita et al., 
2003; Simpson et al., 2004). Knockout of ST3GAL5 in mouse 
embryonic fibroblasts activates an alternative biosynthetic 
pathway of gangliosides from the 0 series (Shevchuk et al., 
2007). Therefore synthesis of GM1a, but not of GM1b, is im-
paired in these cells. Paradoxically, no gangliosides from the 
0 series were detected by thin-layer chromatography in human 
skin fibroblasts derived from patients with point mutations in 
the ST3GAL5 gene, which suggests that no alternative syn-
thetic pathway of gangliosides exists in these cells (Liu et al., 
2008). Whether CTx is able to intoxicate mouse and/or human 
GM3-synthase–deficient fibroblasts remains to be determined, 
but our work shows that human ST3GAL5-null cells are resis-
tant to intoxication by CTx. Thus, either gangliosides from 
the 0 series are not synthesized by these cells, or if GM1b is 
being synthesized, it is not sufficient to deliver CTx to its 
target destination.
We isolated the SLC35A2 and ST3GAL5 mutant cells 
from our selected pool of cells, and using Alexa Fluor 647– 
conjugated CTx, we showed that toxin binding is compromised 
in both cell types. However, in the particular case of ST3GAL5, 
we identified a subset of ST3GAL5-null cells that supports CTx 
binding at levels comparable to wild-type cells. Because dif-
ferential expression of glycosphingolipids at the plasma mem-
brane is cell cycle dependent (Majoul et al., 2002), we speculate 
that the ST3GAL5-null cells have an alternate, possibly cell 
cycle–specific 0 pathway for ganglioside synthesis.
The mutant cells identified in our genetic screen are useful 
tools not only to address the physiological roles of gangliosides 
in human cells but also to dissect binding and trafficking of 
other pathogens and their products. Their retrieval was possible 
through the generation of a cytolethal version of CTx, which 
then enabled us to conduct the genetic screen in haploid cells. 
Chemical mutagenesis in diploid CHO cells has been used to 
generate CTx-resistant clones (Teter and Holmes, 2002), but in 
this case, the identity of the mutant genes that confer resistance 
is unknown and would be difficult to establish. Almost cer-
tainly, such chemically mutagenized cells carry mutations in 
many genes irrelevant for the phenotype selected for, and only 
a complementation test would provide a clue to the nature of the 
mutation. In contrast, our genetic screen in human haploid cells 
yields mutants with defined lesions, readily restored to wild-
type phenotype by provision of the corresponding cDNAs, as 
shown here for SLC35A2.
Based on the ease and versatility of sortase-mediated re-
actions, we envision that the sortase-labeling platform described 
for CTx can be applied to other toxins that display either an ex-
posed cleavable loop or an exposed C terminus, such as heat 
labile enterotoxin (Sixma et al., 1991), shiga toxin (Fraser et al., 
1994), exotoxin A (Allured et al., 1986), and cytolethal distend-
ing toxins (Nesić et al., 2004). The combination of modified 
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Genetic screen in KBM7 cells and isolation of the mutant clones
The genetic screen with the CTx–DTA conjugate was performed on 100 
million mutagenized KBM7 cells (Carette et al., 2011). Cells were exposed 
to 1.5 mg CTx–DTA for 2 wk before harvesting the survivors. Analysis 
of the screen was performed essentially as described previously (Carette 
et al., 2011). In brief, the sequences flanking retroviral insertion sites were 
mapped on the human genome (Table S1) using inverse PCR followed 
by Illumina sequencing. The number of inactivating mutations (i.e., sense 
orientation or present in exon) per individual gene was counted as well 
as the total number of inactivating insertions for all genes. Enrichment of 
a gene in the CTx–DTA–treated population was calculated by comparing 
how often that gene was mutated in the population with how often the 
gene carries an insertion in the untreated control dataset. For each gene, 
a P-value (corrected for false discovery rate) was calculated using the one-
sided Fisher exact test (Table S2). Both WDR85 and SLC35A2 gene hits 
had already been identified in previous genetic screens with diphtheria 
toxin and influenza virus, respectively (Carette et al., 2009), and clonal 
cells defective in these genes were therefore available. To retrieve the 
ST3GAL5 mutant cells, we FACS sorted individual cells from the pool re-
sistant to intoxication by CTx–DTA. Cells were grown until confluent in 
Iscove’s modified Dulbecco’s medium media supplemented with 10% in-
activated fetal calf serum and penicillin/streptomycin at 37°C in a 5% 
CO2 atmosphere. Genomic DNA was then extracted from the different 
individual cell lines using the QiaAmp DNA mini kit (QIAGEN) according 
to the manufacturer’s instructions. The presence of a gene trap within the 
ST3GAL5 gene in any of the isolated cell lines was determined by PCR using 
a forward primer located within the gene trap (5-CTCGGTGGAACCTC-
CAAAT-3) and a reverse primer designed to target the ST3GAL5 gene 
(5-CACACTTCCTCTGCTGCAGTA-3). Two positive clones were identi-
fied and the gene trap insertions were mapped by direct sequencing of 
the PCR product using the forward primer. Absence of the ST3GAL5 tran-
script in the isolated mutant cells was determined by RT-PCR. Total RNA 
was extracted from both the KBM7 and ST3GAL5 mutant cells using the 
RNeasy Mini kit (QIAGEN). cDNA was synthesized using 1 µg of total 
RNA from each sample with the SuperScriptTM III First-Strand synthesis 
system for RT-PCR (Invitrogen). Amplification of ST3GAL5 was performed 
using the following primers: 5-GCCGAGCAATGCCAAGTGAG-3 and 
5-CAGCGCCATTGATGTCTTGG-3. Amplification of SLC35A2 was used 
as a control and performed using the following primers: 5-CTCACAGGC-
GCCTGAAGTAC-3 and 5-GGAAAGTGGCAGCTGGTAG-3.
Microscopy experiments and image acquisition
Toxicity of the various versions of CTx was determined in Vero cells. In 
Fig. 2, cells were grown until 85% confluence in a 24-well plate and then 
intoxicated for 2 h at 37°C with 2 nM CTx (either native or modified as 
indicated). Imaging was performed at room temperature on an inverted 
microscope (Eclipse TE2000-E; Nikon) using a 10× magnification lens 
(Nikon) and a 1× NA. In Fig. 5, Vero cells were treated with 100 ng/ml 
brefeldin A for 1 h before intoxication. Cells were then fixed with 4% 
paraformaldehyde in PBS, permeabilized with 0.1% Triton X-100 in 
PBS, and stained with an antibody directed to giantin (Abcam), phal-
loidin, and Hoechst (Invitrogen). In Fig. 6, binding of CTx to KBM7 and 
to the various mutant cell lines was tested by incubating the cells with 
20 nM CTx-Alexa647 (prepared as described earlier in Materials and 
methods) and LysoTracker Red (Invitrogen) at 37°C for 10 min. Cells were 
washed with PBS, resuspended in Opti-MEM media (Invitrogen), and 
plated onto poly-l-lysine L–coated microscopy slides (Polysciences, 
Inc.). Images were acquired at 37°C using a spinning disk confocal 
microscope (TE2000-U; Nikon) and a 3-W water-cooled laser with an 
acoustic-optic tunable filter (Prairie Technologies), 20× magnification, 
and a 1.4× NA. An Orca ER camera (C4742-95-12ERG; Hamamatsu 
Photonics) and MetaMorph software (Molecular Devices) were used 
for acquisition.
Flow cytometry analysis
FACS assays were performed with the inactive mutant of CTx (E110D/
E112D) conjugated to GGGK-Alexa647 at its CTA1 using sortase as 
described earlier in Materials and methods. Cells were incubated for 
15 min on ice with CTx-Alexa647 and propidium iodide (PI), washed 
with cold PBS supplemented with 1% fetal bovine serum, and submitted 
to FACS analysis immediately (FACS Calibur; BD). Control samples were 
prepared using PI only. Only cells negative for PI staining were gated 
for data acquisition. FlowJo was used to analyze the data. Intensity of 
fluorescence was measured and the percentage maximum is presented in 
the overlaid histograms.
Cloning and expression of G5DTA
The construct pET-15b encoding an LFN-DTA fusion protein was used as 
a template (Addgene 11075; Milne et al., 1995). This plasmid was first 
digested with NcoI to remove the LFN sequence, and the five glycines were 
introduced at the N terminus of DTA by site-directed mutagenesis using 
the following oligonucleotides: 5-CTGGTTCCACGTGGTGGAGGTGGA-
GGTGCTGACGACGTTGTT-3 and its reverse-complement counterpart. The 
His6 LVPR^G5DTA protein was expressed in E. coli BL21(DE3). Cells were 
grown in LB containing 200 µg/ml ampicillin to mid-log phase. Protein ex-
pression was induced with 1 mM IPTG for 3 h at 37°C and cells were har-
vested by centrifugation. The cell pellet was resuspended in 50 mM Tris-Cl, 
150 mM NaCl, and 20 mM imidazole, pH 8.0, supplemented with prote-
ase cocktail inhibitors, lysed by French press, and centrifuged. The cleared 
lysate was then applied to a Ni-NTA column equilibrated with 50 mM 
Tris-Cl, 150 mM NaCl, and 20 mM imidazole, pH 8.0. The column was 
washed with 20 column volumes of buffer and the protein was eluted with 
50 mM Tris-Cl, 150 mM NaCl, and 300 mM imidazole, pH 8.0. The 
buffer was exchanged to 20 mM Tris-Cl and 150 mM NaCl, pH 8.0, 
using a desalting column (PD10 Sephadex; GE Healthcare). The mate-
rial was concentrated to 1 ml using centrifugal concentrators (Vivapsin 
500; Sigma-Aldrich) and subjected to thrombin cleavage (Thrombin Clean-
Cleave Kit; Sigma-Aldrich) for 16 h at 25°C. Cleavage was monitored by 
SDS-PAGE followed by Coomassie staining upon which the reaction was 
filtered to remove the thrombin beads. G5DTA was further purified by size 
exclusion chromatography on a HiLoad 16/60 Superdex 75 column (GE 
Healthcare), eluting with 50 mM Tris-Cl, 150 mM NaCl, and 10% glycerol 
(wt/vol), pH 8.0, at a flow rate of 1 ml/min. Fractions containing G5DTA 
were pooled, concentrated, aliquoted, and stored at 80°C. Protein con-
centration was estimated by UV-visible spectroscopy using the absorbance 
of G5DTA at 280 nM (calculated extinction coefficient 25,900 M/cm).
Sortase-labeling reactions
Sortase AStaph was expressed and purified as described previously (Popp 
et al., 2007). In brief, sortase AStaph (residues 26–206) containing an 
N-terminal His6 tag was expressed in E. coli BL21(DE3). Cells were grown 
in LB containing 0.1 mg/ml ampicillin to an optical density of 0.6 at 
600 nm. Protein expression was induced with 1 mM IPTG for 3 h at 37°C. 
Cells were harvested by centrifugation, and the pellet was resuspended in 
50 mM Tris-Cl, 150 mM NaCl, and 10 mM imidazole, pH 8.0, supple-
mented with protease cocktail inhibitors, then lysed a by French press and 
centrifuged. The cleared lysate was then applied to a Ni-NTA column pre-
viously equilibrated with the resuspension buffer. The column was washed 
with 20 column volumes of 50 mM Tris-Cl, 150 mM NaCl, and 10 mM 
imidazole, pH 8.0. The protein was eluted with 5 column volumes of 
50 mM Tris-Cl, 150 mM NaCl, and 300 mM imidazole, pH 8.0. The buf-
fer was exchanged to 20 mM Tris-Cl, 150 mM NaCl, and 10% glycerol, 
pH 8.0, using a desalting column (PD10 Sephadex). Protein concentration 
was estimated with a Bradford assay. The purified protein was concen-
trated to a 0.6-mM stock solution, aliquoted, and stored at 80°C until 
further use.
Before a sortase reaction, the engineered sortaggable loop of chol-
era toxin was cleaved with immobilized trypsin (Thermo Fisher Scientific) at 
25°C for 90 min (2 µl of a 50% slurry per 200 µg of protein). Cleavage was 
monitored by SDS-PAGE under reducing conditions. Upon complete cleav-
age of the loop, trypsin beads were removed by filtration. Typical sortase 
reactions contained 40 µM CTx, 50 µM sortase A, and 1 mM nucleophile 
in sortase buffer (50 mM Tris-Cl, 150 mM NaCl, and 10 mM CaCl2). The 
reactions were incubated at 37°C for 5 h (when using small probes) or at 
25°C for 16 h (when using proteins as nucleophiles). The reaction buffer 
was exchanged to PBS containing no CaCl2 using a NAP Sephadex column 
(GE Healthcare). This step starkly reduces sortase activity, which is calcium 
dependent, and also allows removal of excess free peptide. The final prepa-
rations were stable at 4°C for at least 2 wk. Although high ligation yields are 
achieved using the conditions described, the CTx–G5DTA conjugate used to 
intoxicate Vero cells in Fig. 5 C was further purified by size exclusion chro-
matography as described for G5DTA. Fractions containing pure CTx–G5DTA 
were pooled, concentrated, and aliquoted, and the protein concentration 
was determined with a Bradford assay.
Cell proliferation assay
Cells were treated continuously for 16 h at 37°C in a 5% CO2 atmosphere 
with different amounts of the various toxins and controls as indicated in the 
legend to Fig. 5.
Cell viability was determined using the XTT cell proliferation kit from 
Roche according to the manufacturer’s instructions.
 o
n
 February 6, 2012
jcb.rupress.org
D
ow
nloaded from
 
Published November 28, 2011
763New tools to study toxin trafficking • Guimaraes et al.
Carette, J.E., C.P. Guimaraes, I. Wuethrich, V.A. Blomen, M. Varadarajan, C. Sun, 
G. Bell, B. Yuan, M.K. Muellner, S.M. Nijman, et al. 2011. Global gene 
disruption in human cells to assign genes to phenotypes by deep sequencing. 
Nat. Biotechnol. 29:542–546. http://dx.doi.org/10.1038/nbt.1857
Chaudhary, V.K., Y. Jinno, D. FitzGerald, and I. Pastan. 1990. Pseudomonas 
exotoxin contains a specific sequence at the carboxyl terminus that is re-
quired for cytotoxicity. Proc. Natl. Acad. Sci. USA. 87:308–312. http://
dx.doi.org/10.1073/pnas.87.1.308
Chen, I., M. Howarth, W. Lin, and A.Y. Ting. 2005. Site-specific labeling of 
cell surface proteins with biophysical probes using biotin ligase. Nat. 
Methods. 2:99–104. http://dx.doi.org/10.1038/nmeth735
Collier, R.J. 2001. Understanding the mode of action of diphtheria toxin: a per-
spective on progress during the 20th century. Toxicon. 39:1793–1803. 
http://dx.doi.org/10.1016/S0041-0101(01)00165-9
Dertzbaugh, M.T., and L.M. Cox. 1998. The affinity of cholera toxin for Ni2+ ion. 
Protein Eng. 11:577–581. http://dx.doi.org/10.1093/protein/11.7.577
Dixit, G., C. Mikoryak, T. Hayslett, A. Bhat, and R.K. Draper. 2008. Cholera 
toxin up-regulates endoplasmic reticulum proteins that correlate with 
sensitivity to the toxin. Exp. Biol. Med. (Maywood). 233:163–175. http://
dx.doi.org/10.3181/0705-RM-132
Doms, R.W., G. Russ, and J.W. Yewdell. 1989. Brefeldin A redistributes resi-
dent and itinerant Golgi proteins to the endoplasmic reticulum. J. Cell 
Biol. 109:61–72. http://dx.doi.org/10.1083/jcb.109.1.61
Donta, S.T., S.R. Kreiter, and G. Wendelschafer-Crabb. 1976. Morphological 
and steroidogenic changes in cultured adrenal tumor cells induced by a 
subunit of cholera enterotoxin. Infect. Immun. 13:1479–1482.
Dougan, S.K., C.C. Hu, M.E. Paquet, M.B. Greenblatt, J. Kim, B.N. Lilley, N. 
Watson, and H.L. Ploegh. 2011. Derlin-2-deficient mice reveal an essen-
tial role for protein dislocation in chondrocytes. Mol. Cell. Biol. 31:1145–
1159. http://dx.doi.org/10.1128/MCB.00967-10
Fraser, M.E., M.M. Chernaia, Y.V. Kozlov, and M.N. James. 1994. Crystal 
structure of the holotoxin from Shigella dysenteriae at 2.5 A resolution. 
Nat. Struct. Biol. 1:59–64. http://dx.doi.org/10.1038/nsb0194-59
Fujinaga, Y., A.A. Wolf, C. Rodighiero, H. Wheeler, B. Tsai, L. Allen, 
M.G. Jobling, T. Rapoport, R.K. Holmes, and W.I. Lencer. 2003. 
Gangliosides that associate with lipid rafts mediate transport of chol-
era and related toxins from the plasma membrane to endoplasmic re-
ticulm. Mol. Biol. Cell. 14:4783–4793. http://dx.doi.org/10.1091/mbc 
.E03-06-0354
Guerrant, R.L., L.L. Brunton, T.C. Schnaitman, L.I. Rebhun, and A.G. Gilman. 
1974. Cyclic adenosine monophosphate and alteration of Chinese 
hamster ovary cell morphology: a rapid, sensitive in vitro assay for the 
enterotoxins of Vibrio cholerae and Escherichia coli. Infect. Immun. 10: 
320–327.
Hazes, B., and R.J. Read. 1997. Accumulating evidence suggests that several 
AB-toxins subvert the endoplasmic reticulum-associated protein deg-
radation pathway to enter target cells. Biochemistry. 36:11051–11054. 
http://dx.doi.org/10.1021/bi971383p
Heyningen, S.V. 1974. Cholera toxin: interaction of subunits with ganglioside GM1. 
Science. 183:656–657. http://dx.doi.org/10.1126/science.183.4125.656
Jobling, M.G., and R.K. Holmes. 2000. Identification of motifs in cholera 
toxin A1 polypeptide that are required for its interaction with human 
ADP-ribosylation factor 6 in a bacterial two-hybrid system. Proc. 
Natl. Acad. Sci. USA. 97:14662–14667. http://dx.doi.org/10.1073/pnas 
.011442598
Jobling, M.G., and R.K. Holmes. 2001. Biological and biochemical characteriza-
tion of variant A subunits of cholera toxin constructed by site-directed 
mutagenesis. J. Bacteriol. 183:4024–4032. http://dx.doi.org/10.1128/ 
JB.183.13.4024-4032.2001
Jobling, M.G., L.M. Palmer, J.L. Erbe, and R.K. Holmes. 1997. Construction 
and characterization of versatile cloning vectors for efficient delivery 
of native foreign proteins to the periplasm of Escherichia coli. Plasmid. 
38:158–173. http://dx.doi.org/10.1006/plas.1997.1309
Kahn, R.A., and A.G. Gilman. 1984. ADP-ribosylation of Gs promotes the dis-
sociation of its alpha and beta subunits. J. Biol. Chem. 259:6235–6240.
Kassis, S., J. Hagmann, P.H. Fishman, P.P. Chang, and J. Moss. 1982. Mechanism 
of action of cholera toxin on intact cells. Generation of A1 peptide and 
activation of adenylate cyclase. J. Biol. Chem. 257:12148–12152.
Keppler, A., S. Gendreizig, T. Gronemeyer, H. Pick, H. Vogel, and K. Johnsson. 
2003. A general method for the covalent labeling of fusion proteins 
with small molecules in vivo. Nat. Biotechnol. 21:86–89. http://dx.doi 
.org/10.1038/nbt765
Lencer, W.I., and B. Tsai. 2003. The intracellular voyage of cholera toxin: 
going retro. Trends Biochem. Sci. 28:639–645. http://dx.doi.org/10.1016/ 
j.tibs.2003.10.002
Lencer, W.I., C. Delp, M.R. Neutra, and J.L. Madara. 1992. Mechanism of chol-
era toxin action on a polarized human intestinal epithelial cell line: role of 
Glycosylation assay
Vero cells (85% confluent in a 10-cm dish) were trypsinized with 0.05% 
Trypsin-EDTA and harvested by centrifugation. Upon washing with PBS, 
the cells were resuspended in 100 µl of Opti-MEM media and intoxicated 
with CTx-G3K(biotin)NNSTG at a final concentration of 20 nM on ice for 
10 min. The cells were then diluted in 10 ml Opti-MEM and incubated at 
37°C. 1-ml aliquots were taken at the indicated time points. The cells were 
sedimented, washed with PBS, and snap frozen. For SDS-PAGE, the cells 
were thawed on ice and lysed in 0.1% SDS (vol/vol) in 50 mM Tris-Cl, 
pH 8.0, in the presence of 0.5 mg/ml PMSF. Protein concentration was 
determined with a bicinchoninic acid assay (Thermo Fisher Scientific), and 
equal amounts of total protein were loaded onto a 10% SDS-PAGE gel. 
The biotinylated CTx was visualized by immunoblotting using a strepta-
vidin–HRP conjugate and ECL detection substrates. The film was scanned 
and the bands were quantified using the public-domain ImageJ program 
(National Institutes of Health).
Digestion with Endoglycosidase H and PNGase F (New England 
Biolabs, Inc.) was performed at 37°C for 1 h after retrieval of biotinylated 
CTx species from the cell lysates using streptavidin beads (Sigma-Aldrich).
Miscellaneous
Fluorescent gel images were obtained using a variable mode imager (Ty-
phoon 9200; GE Healthcare). For mass-spectrometry, the protein bands of 
interest were excised, subjected to digestion with trypsin or chymotrypsin, and 
analyzed by electrospray ionization tandem mass spectrometry (MS/MS).
Online supplemental material
Fig. S1 shows optimization of the sortase-mediated reactions to label 
CTA1 in the context of the holotoxin. Fig. S2 shows mass spectrometry 
data on the identity of the CTx–DTA conjugate. Table S1 shows the DNA 
sequences flanking each of the retroviral insertion sites. Table S2 shows 
the data analysis for the results obtained in the genetic screen. Online 
supplemental material is available at http://www.jcb.org/cgi/content/ 
full/jcb.201108103/DC1.
We thank T. DiCesare for graphics support, and C. Araneo and E. Guillen for 
help with FACS sorting and FACS analysis.
C.P. Guimaraes was supported by a fellowship from Fundacao Cien-
cia Tecnologia, Portugal.
Submitted: 16 August 2011
Accepted: 28 October 2011
References
Allured, V.S., R.J. Collier, S.F. Carroll, and D.B. McKay. 1986. Structure of 
exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. 
Proc. Natl. Acad. Sci. USA. 83:1320–1324. http://dx.doi.org/10.1073/ 
pnas.83.5.1320
Antos, J.M., G.M. Miller, G.M. Grotenbreg, and H.L. Ploegh. 2008. Lipid modi-
fication of proteins through sortase-catalyzed transpeptidation. J. Am. 
Chem. Soc. 130:16338–16343. http://dx.doi.org/10.1021/ja806779e
Antos, J.M., M.W. Popp, R. Ernst, G.L. Chew, E. Spooner, and H.L. Ploegh. 
2009. A straight path to circular proteins. J. Biol. Chem. 284:16028–
16036. http://dx.doi.org/10.1074/jbc.M901752200
Arunachalam, B., U.T. Phan, H.J. Geuze, and P. Cresswell. 2000. Enzymatic 
reduction of disulfide bonds in lysosomes: characterization of a gamma-
interferon-inducible lysosomal thiol reductase (GILT). Proc. Natl. Acad. 
Sci. USA. 97:745–750. http://dx.doi.org/10.1073/pnas.97.2.745
Bacia, K., I.V. Majoul, and P. Schwille. 2002. Probing the endocytic pathway in 
live cells using dual-color fluorescence cross-correlation analysis. Biophys. 
J. 83:1184–1193. http://dx.doi.org/10.1016/S0006-3495(02)75242-9
Bastiaens, P.I., I.V. Majoul, P.J. Verveer, H.D. Söling, and T.M. Jovin. 1996. 
Imaging the intracellular trafficking and state of the AB5 quaternary 
structure of cholera toxin. EMBO J. 15:4246–4253.
Bernardi, K.M., M.L. Forster, W.I. Lencer, and B. Tsai. 2008. Derlin-1 facili-
tates the retro-translocation of cholera toxin. Mol. Biol. Cell. 19:877–884. 
http://dx.doi.org/10.1091/mbc.E07-08-0755
Bernardi, K.M., J.M. Williams, M. Kikkert, S. van Voorden, E.J. Wiertz, Y. Ye, 
and B. Tsai. 2010. The E3 ubiquitin ligases Hrd1 and gp78 bind to and 
promote cholera toxin retro-translocation. Mol. Biol. Cell. 21:140–151. 
http://dx.doi.org/10.1091/mbc.E09-07-0586
Carette, J.E., C.P. Guimaraes, M. Varadarajan, A.S. Park, I. Wuethrich, A. 
Godarova, M. Kotecki, B.H. Cochran, E. Spooner, H.L. Ploegh, and T.R. 
Brummelkamp. 2009. Haploid genetic screens in human cells identify 
host factors used by pathogens. Science. 326:1231–1235. http://dx.doi 
.org/10.1126/science.1178955
 o
n
 February 6, 2012
jcb.rupress.org
D
ow
nloaded from
 
Published November 28, 2011
JCB • VOLUME 195 • NUMBER 5 • 2011 764
Popp, M.W., J.M. Antos, G.M. Grotenbreg, E. Spooner, and H.L. Ploegh. 2007. 
Sortagging: a versatile method for protein labeling. Nat. Chem. Biol. 
3:707–708. http://dx.doi.org/10.1038/nchembio.2007.31
Rapak, A., P.O. Falnes, and S. Olsnes. 1997. Retrograde transport of mutant ricin 
to the endoplasmic reticulum with subsequent translocation to cytosol. 
Proc. Natl. Acad. Sci. USA. 94:3783–3788. http://dx.doi.org/10.1073/ 
pnas.94.8.3783
Saslowsky, D.E., J.A. Cho, H. Chinnapen, R.H. Massol, D.J. Chinnapen, J.S. 
Wagner, H.E. De Luca, W. Kam, B.H. Paw, and W.I. Lencer. 2010. 
Intoxication of zebrafish and mammalian cells by cholera toxin depends 
on the flotillin/reggie proteins but not Derlin-1 or -2. J. Clin. Invest. 
120:4399–4409. http://dx.doi.org/10.1172/JCI42958
Schafer, D.E., W.D. Lust, B. Sircar, and N.D. Goldberg. 1970. Elevated concen-
tration of adenosine 3:5-cyclic monophosphate in intestinal mucosa 
after treatment with cholera toxin. Proc. Natl. Acad. Sci. USA. 67:851–856. 
http://dx.doi.org/10.1073/pnas.67.2.851
Schmitz, A., H. Herrgen, A. Winkeler, and V. Herzog. 2000. Cholera toxin is ex-
ported from microsomes by the Sec61p complex. J. Cell Biol. 148:1203–
1212. http://dx.doi.org/10.1083/jcb.148.6.1203
Shevchuk, N.A., Y. Hathout, O. Epifano, Y. Su, Y. Liu, M. Sutherland, and 
S. Ladisch. 2007. Alteration of ganglioside synthesis by GM3 synthase 
knockout in murine embryonic fibroblasts. Biochim. Biophys. Acta. 
1771:1226–1234.
Simpson, M.A., H. Cross, C. Proukakis, D.A. Priestman, D.C. Neville, G. 
Reinkensmeier, H. Wang, M. Wiznitzer, K. Gurtz, A. Verganelaki, et al. 
2004. Infantile-onset symptomatic epilepsy syndrome caused by a 
homozygous loss-of-function mutation of GM3 synthase. Nat. Genet. 
36:1225–1229. http://dx.doi.org/10.1038/ng1460
Sixma, T.K., S.E. Pronk, K.H. Kalk, E.S. Wartna, B.A. van Zanten, B. Witholt, 
and W.G. Hol. 1991. Crystal structure of a cholera toxin-related heat-
labile enterotoxin from E. coli. Nature. 351:371–377. http://dx.doi.org/ 
10.1038/351371a0
Taylor, M., T. Banerjee, S. Ray, S.A. Tatulian, and K. Teter. 2011. Protein-disul-
fide isomerase displaces the cholera toxin A1 subunit from the holotoxin 
without unfolding the A1 subunit. J. Biol. Chem. 286:22090–22100. http:// 
dx.doi.org/10.1074/jbc.M111.237966
Teter, K., and R.K. Holmes. 2002. Inhibition of endoplasmic reticulum-associated 
degradation in CHO cells resistant to cholera toxin, Pseudomonas 
aeruginosa exotoxin A, and ricin. Infect. Immun. 70:6172–6179. http://
dx.doi.org/10.1128/IAI.70.11.6172-6179.2002
Teter, K., R.L. Allyn, M.G. Jobling, and R.K. Holmes. 2002. Transfer of the 
cholera toxin A1 polypeptide from the endoplasmic reticulum to the 
cytosol is a rapid process facilitated by the endoplasmic reticulum- 
associated degradation pathway. Infect. Immun. 70:6166–6171. http://
dx.doi.org/10.1128/IAI.70.11.6166-6171.2002
Ton-That, H., G. Liu, S.K. Mazmanian, K.F. Faull, and O. Schneewind. 1999. 
Purification and characterization of sortase, the transpeptidase that 
cleaves surface proteins of Staphylococcus aureus at the LPXTG motif. 
Proc. Natl. Acad. Sci. USA. 96:12424–12429. http://dx.doi.org/10.1073/ 
pnas.96.22.12424
Tsai, B., C. Rodighiero, W.I. Lencer, and T.A. Rapoport. 2001. Protein disulfide 
isomerase acts as a redox-dependent chaperone to unfold cholera toxin. 
Cell. 104:937–948. http://dx.doi.org/10.1016/S0092-8674(01)00289-6
Tsukiji, S., and T. Nagamune. 2009. Sortase-mediated ligation: a gift from 
Gram-positive bacteria to protein engineering. ChemBioChem. 10:787–
798. http://dx.doi.org/10.1002/cbic.200800724
Wernick, N.L., H. De Luca, W.R. Kam, and W.I. Lencer. 2010a. N-terminal 
extension of the cholera toxin A1-chain causes rapid degradation after 
retrotranslocation from endoplasmic reticulum to cytosol. J. Biol. Chem. 
285:6145–6152. http://dx.doi.org/10.1074/jbc.M109.062067
Wernick, N.L.B., D.-F. Chinnapen, J.A. Cho, and W.I. Lencer. 2010b. Cholera 
toxin: an intracellular journey into the cytosol by way of the endoplasmic 
reticulum. Toxins. 2:310–325. http://dx.doi.org/10.3390/toxins2030310
Winkeler, A., D. Gödderz, V. Herzog, and A. Schmitz. 2003. BiP-dependent export 
of cholera toxin from endoplasmic reticulum-derived microsomes. FEBS 
Lett. 554:439–442. http://dx.doi.org/10.1016/S0014-5793(03)01217-1
Yamashita, T., A. Hashiramoto, M. Haluzik, H. Mizukami, S. Beck, A. Norton, 
M. Kono, S. Tsuji, J.L. Daniotti, N. Werth, et al. 2003. Enhanced insulin 
sensitivity in mice lacking ganglioside GM3. Proc. Natl. Acad. Sci. USA. 
100:3445–3449. http://dx.doi.org/10.1073/pnas.0635898100
Yoshida, T., C.C. Chen, M.S. Zhang, and H.C. Wu. 1991. Disruption of the 
Golgi apparatus by brefeldin A inhibits the cytotoxicity of ricin, modec-
cin, and Pseudomonas toxin. Exp. Cell Res. 192:389–395. http://dx.doi 
.org/10.1016/0014-4827(91)90056-Z
Zhang, R.G., D.L. Scott, M.L. Westbrook, S. Nance, B.D. Spangler, G.G. Shipley, 
and E.M. Westbrook. 1995. The three-dimensional crystal structure of cholera 
toxin. J. Mol. Biol. 251:563–573. http://dx.doi.org/10.1006/jmbi.1995.0456
vesicular traffic. J. Cell Biol. 117:1197–1209. http://dx.doi.org/10.1083/ 
jcb.117.6.1197
Lencer, W.I., J.B. de Almeida, S. Moe, J.L. Stow, D.A. Ausiello, and J.L. 
Madara. 1993. Entry of cholera toxin into polarized human intestinal epi-
thelial cells. Identification of an early brefeldin A sensitive event required 
for A1-peptide generation. J. Clin. Invest. 92:2941–2951. http://dx.doi 
.org/10.1172/JCI116917
Lencer, W.I., C. Constable, S. Moe, M.G. Jobling, H.M. Webb, S. Ruston, 
J.L. Madara, T.R. Hirst, and R.K. Holmes. 1995. Targeting of cholera 
toxin and Escherichia coli heat labile toxin in polarized epithelia: role 
of COOH-terminal KDEL. J. Cell Biol. 131:951–962. http://dx.doi 
.org/10.1083/jcb.131.4.951
Lippincott-Schwartz, J., L.C. Yuan, J.S. Bonifacino, and R.D. Klausner. 1989. 
Rapid redistribution of Golgi proteins into the ER in cells treated with 
brefeldin A: evidence for membrane cycling from Golgi to ER. Cell. 
56:801–813. http://dx.doi.org/10.1016/0092-8674(89)90685-5
Liu, S., G.T. Milne, J.G. Kuremsky, G.R. Fink, and S.H. Leppla. 2004. 
Identification of the proteins required for biosynthesis of diphthamide, 
the target of bacterial ADP-ribosylating toxins on translation elonga-
tion factor 2. Mol. Cell. Biol. 24:9487–9497. http://dx.doi.org/10.1128/ 
MCB.24.21.9487-9497.2004
Liu, Y., Y. Su, M. Wiznitzer, O. Epifano, and S. Ladisch. 2008. Ganglioside de-
pletion and EGF responses of human GM3 synthase-deficient fibroblasts. 
Glycobiology. 18:593–601. http://dx.doi.org/10.1093/glycob/cwn039
Maccioni, H.J., R. Quiroga, and M.L. Ferrari. 2011. Cellular and molecular biol-
ogy of glycosphingolipid glycosylation. J. Neurochem. 117:589–602.
Maglione, V., P. Marchi, A. Di Pardo, S. Lingrell, M. Horkey, E. Tidmarsh, 
and S. Sipione. 2010. Impaired ganglioside metabolism in Huntington’s 
disease and neuroprotective role of GM1. J. Neurosci. 30:4072–4080. 
http://dx.doi.org/10.1523/JNEUROSCI.6348-09.2010
Majoul, I., D. Ferrari, and H.D. Söling. 1997. Reduction of protein disulfide 
bonds in an oxidizing environment. The disulfide bridge of cholera 
toxin A-subunit is reduced in the endoplasmic reticulum. FEBS Lett. 
401:104–108. http://dx.doi.org/10.1016/S0014-5793(96)01447-0
Majoul, I., T. Schmidt, M. Pomasanova, E. Boutkevich, Y. Kozlov, and H.D. 
Söling. 2002. Differential expression of receptors for Shiga and Cholera 
toxin is regulated by the cell cycle. J. Cell Sci. 115:817–826.
Mekalanos, J.J., R.J. Collier, and W.R. Romig. 1979. Enzymic activity of chol-
era toxin. II. Relationships to proteolytic processing, disulfide bond re-
duction, and subunit composition. J. Biol. Chem. 254:5855–5861.
Milne, J.C., S.R. Blanke, P.C. Hanna, and R.J. Collier. 1995. Protective antigen-
binding domain of anthrax lethal factor mediates translocation of a heter-
ologous protein fused to its amino- or carboxy-terminus. Mol. Microbiol. 
15:661–666. http://dx.doi.org/10.1111/j.1365-2958.1995.tb02375.x
Miyazaki, Y., X. Sun, H. Uchida, J. Zhang, and S. Nimer. 1996. MEF, a novel 
transcription factor with an Elf-1 like DNA binding domain but distinct 
transcriptional activating properties. Oncogene. 13:1721–1729.
Naglich, J.G., J.E. Metherall, D.W. Russell, and L. Eidels. 1992. Expression clon-
ing of a diphtheria toxin receptor: identity with a heparin-binding EGF-like 
growth factor precursor. Cell. 69:1051–1061. http://dx.doi.org/10.1016/ 
0092-8674(92)90623-K
Nambiar, M.P., T. Oda, C. Chen, Y. Kuwazuru, and H.C. Wu. 1993. Involvement 
of the Golgi region in the intracellular trafficking of cholera toxin. J. Cell. 
Physiol. 154:222–228. http://dx.doi.org/10.1002/jcp.1041540203
Navarre, W.W., and O. Schneewind. 1994. Proteolytic cleavage and cell wall 
anchoring at the LPXTG motif of surface proteins in gram-positive 
bacteria. Mol. Microbiol. 14:115–121. http://dx.doi.org/10.1111/j.1365-
2958.1994.tb01271.x
Nery, F.C., I.A. Armata, J.E. Farley, J.A. Cho, U. Yaqub, P. Chen, C.C. da Hora, 
Q. Wang, M. Tagaya, C. Klein, et al. 2011. TorsinA participates in endo-
plasmic reticulum-associated degradation. Nat Commun. 2:393. http://
dx.doi.org/10.1038/ncomms1383
Nesić, D., Y. Hsu, and C.E. Stebbins. 2004. Assembly and function of a bacterial 
genotoxin. Nature. 429:429–433. http://dx.doi.org/10.1038/nature02532
Orlandi, P.A. 1997. Protein-disulfide isomerase-mediated reduction of the A 
subunit of cholera toxin in a human intestinal cell line. J. Biol. Chem. 
272:4591–4599.
Orlandi, P.A., P.K. Curran, and P.H. Fishman. 1993. Brefeldin A blocks the 
response of cultured cells to cholera toxin. Implications for intracellular 
trafficking in toxin action. J. Biol. Chem. 268:12010–12016.
Pande, A.H., P. Scaglione, M. Taylor, K.N. Nemec, S. Tuthill, D. Moe, R.K. 
Holmes, S.A. Tatulian, and K. Teter. 2007. Conformational instability 
of the cholera toxin A1 polypeptide. J. Mol. Biol. 374:1114–1128. http://
dx.doi.org/10.1016/j.jmb.2007.10.025
Popp, M.W., and H.L. Ploegh. 2011. Making and breaking peptide bonds: pro-
tein engineering using sortase. Angew. Chem. Int. Ed. Engl. 50:5024–
5032. http://dx.doi.org/10.1002/anie.201008267
 o
n
 February 6, 2012
jcb.rupress.org
D
ow
nloaded from
 
Published November 28, 2011
